Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Edit functionality is currently unavailable.

Fang Xie, Ph.D.

Title
Institution
Department
Address
Phone
Fax
Profile Picture

Overview
After graduation with a PhD in Genetics at Fudan University, Dr. Fang Xie joined Mayo Clinic and his research was focused on endocrine therapy resistance in hormone-naive breast cancer. During his time at Mayo, he also generated a series of patient-derived xenografts (PDXs) using bone biopsies from patients with metastatic castration resistant prostate cancer (CRPC). To extend his research on drug resistance in CRPC and pursue a scientific career as a translational scientist, Dr. Xie joined the Balk Lab at BIDMC/HMS in 2017. Dr. Xie is currently collaborating with a physician-scientist, Dr. Rupal Bhatt, on studies aimed at deciphering the molecular mechanisms underlying resistance in CRPC patients following the failure of taxane-based therapies. One of his recent findings is the increased sensitivity of docetaxel-resistant CRPC PDX tumors to BH3 mimetics such as Navitoclax and S63845. The active hypothesis for this study is that taxanes kill interphase prostate cancer cells in vivo through induction of apoptosis and that blocking the function of pro-survival proteins may help overcome taxane resistance. In addition to these studies focused on taxane resistance, Dr. Xie is also undertaking several large screening projects, including high through-put drug screening on prostate cancer organoids to identify drugs which enhance the in vivo efficacy of docetaxel in CRPC patients and a whole genome CRISPR screen of enzalutamide-resistant prostate cancer cell lines to identify novel therapeutic targets and vulnerabilities in the castration-resistant setting.

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Li L, Zhang JW, Jenkins G, Xie F, Carlson EE, Fridley BL, Bamlet WR, Petersen GM, McWilliams RR, Wang L. Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer. Pharmacogenet Genomics. 2016 Dec; 26(12):527-537. PMID: 27749787.
    Citations: 1     Fields:    Translation:HumansCells
  2. Ingle JN, Xie F, Ellis MJ, Goss PE, Shepherd LE, Chapman JW, Chen BE, Kubo M, Furukawa Y, Momozawa Y, Stearns V, Pritchard KI, Barman P, Carlson EE, Goetz MP, Weinshilboum RM, Kalari KR, Wang L. Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. Cancer Res. 2016 12 01; 76(23):7012-7023. PMID: 27758888.
    Citations: 11     Fields:    Translation:HumansCells
  3. Tang L, Zhu H, Yang X, Xie F, Peng J, Jiang D, Xie J, Qi M, Yu L. Shizukaol D, a Dimeric Sesquiterpene Isolated from Chloranthus serratus, Represses the Growth of Human Liver Cancer Cells by Modulating Wnt Signalling Pathway. PLoS One. 2016; 11(3):e0152012. PMID: 27010735.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  4. Kohli M, Wang L, Xie F, Sicotte H, Yin P, Dehm SM, Hart SN, Vedell PT, Barman P, Qin R, Mahoney DW, Carlson RE, Eckel-Passow JE, Atwell TD, Eiken PW, McMenomy BP, Wieben ED, Jha G, Jimenez RE, Weinshilboum R, Wang L. Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy. PLoS One. 2015; 10(12):e0145176. PMID: 26695660.
    Citations: 4     Fields:    Translation:HumansAnimals
  5. Liu T, Fang Y, Zhang H, Deng M, Gao B, Niu N, Yu J, Lee S, Kim J, Qin B, Xie F, Evans D, Wang L, Lou W, Lou Z. HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy. Cancer Res. 2016 Feb 01; 76(3):572-81. PMID: 26676747.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  6. Xie F, Zhu H, Zhang H, Lang Q, Tang L, Huang Q, Yu L. In vitro and in vivo characterization of a benzofuran derivative, a potential anticancer agent, as a novel Aurora B kinase inhibitor. Eur J Med Chem. 2015 Jan 07; 89:310-9. PMID: 25462247.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  7. Hu XH, Ding LY, Huang WX, Yang XM, Xie F, Xu M, Yu L. (-)-Epigallocatechin-3-gallate, a potential inhibitor to human dicarbonyl/L-xylulose reductase. J Biochem. 2013 Aug; 154(2):167-75. PMID: 23661708.
    Citations:    Fields:    Translation:HumansCells
  8. Zhu H, Liu Z, Tang L, Liu J, Zhou M, Xie F, Wang Z, Wang Y, Shen S, Hu L, Yu L. Reversal of P-gp and MRP1-mediated multidrug resistance by H6, a gypenoside aglycon from Gynostemma pentaphyllum, in vincristine-resistant human oral cancer (KB/VCR) cells. Eur J Pharmacol. 2012 Dec 05; 696(1-3):43-53. PMID: 23051672.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  9. Xie F, Lang Q, Zhou M, Zhang H, Zhang Z, Zhang Y, Wan B, Huang Q, Yu L. The dietary flavonoid luteolin inhibits Aurora B kinase activity and blocks proliferation of cancer cells. Eur J Pharm Sci. 2012 Aug 15; 46(5):388-96. PMID: 22449725.
    Citations: 7     Fields:    Translation:HumansCells
  10. Pang X, Zhang M, Zhou L, Xie F, Lu H, He W, Jiang S, Yu L, Zhang X. Discovery of a potent peptidic cyclophilin A inhibitor Trp-Gly-Pro. Eur J Med Chem. 2011 May; 46(5):1701-5. PMID: 21396746.
    Citations: 2     Fields:    Translation:HumansCells
  11. Pang X, Zhou L, Zhang M, Xie F, Yu L, Zhang L, Xu L, Zhang X. A mathematical model for peptide inhibitor design. J Comput Biol. 2010 Aug; 17(8):1081-93. PMID: 20726794.
    Citations:    Fields:    Translation:Cells
  12. Zhang Y, Lang Q, Li J, Xie F, Wan B, Yu L. Identification and characterization of human LYPD6, a new member of the Ly-6 superfamily. Mol Biol Rep. 2010 Apr; 37(4):2055-62. PMID: 19653121.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  13. Lang Q, Zhang H, Li J, Xie F, Zhang Y, Wan B, Yu L. 3-Hydroxyflavone inhibits endogenous Aurora B and induces growth inhibition of cancer cell line. Mol Biol Rep. 2010 Mar; 37(3):1577-83. PMID: 19437133.
    Citations: 3     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Xie's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (118)
Explore
_
Co-Authors (1)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.